Palo Alto, California, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Rayont Inc. ("Rayont" or the "Company") (OTC PINK: RAYT), an international personalized natural healthcare company, today reported financial results for the twelve-month ended June 30, 2022.
Business Highlights Within the Twelve-Month ended June 30, 2022:
Ms. Marshini Moodley, CEO and CFO, said, "We recorded a decline in both the revenue and gross profit for the period ended 30 June 2022 compared to same period last year, mainly due to increase in cost of raw materials and lead time of supply chain in Prema Life operations. We also disposed Rayont Technologies operations in Australia and Malaysia resulting in drop of revenues and gross profit."
Twelve-month Ending June 30, 2022, Financial Results:
| | | Twelve Months Ended June 30, | |
| | | 2022 | | | 2021 | |
| Revenues | | $ | 2,839,357 | | | $ | 2,969,599 | |
| Gross Profit | | $ | 1,382,624 | | | $ | 1,748,573 | |
Improved Balance Sheet Results
| | | June 30,
2022 | | | | June 30,
2021 | |
| Cash | | $ | 185,782 | | | $ | 243,610 | |
| Total Assets | | $ | 14,193,235 | | | $ | 7,157,352 | |
| Total Liabilities | | $ | 9,099,623 | | | $ | 3,430,326 | |
| Total Stockholders' Equity | | $ | 5,093,612 | | | $ | 3,727,026 | |
Marshini Moodley added, "Our yearly performance reflecting increased total asset portfolio and total stockholders' equity. The working capital deficit decreased from $1,456,964 that was on June 30, 2021, to $83,884 as of June 30, 2022. Our cash reserves have decreased due to capital investments and servicing loan interest received to cover different investments done from the Company during the year".
Strategies for Growth
During this financial year we continue to undertake several key activities aimed to improve the overall performance of Rayont Inc namely:
- Consolidate the operations of Prema Life with that of Tugun Compounding Pharmacy to drive cost reduction and efficiencies across both operations.
- Launch Health Script telehealth platform for naturopaths globally with key markets focus Australia and the USA.
- Continue with smaller acquisitions that can contribute to revenue growth and synergies across the group. We expect that the acquisitions made to date will contribute to significant revenue and profit growth this financial year.
These activities are being worked on and we will communicate their completions as we achieve them.
About Rayont Inc.
Rayont, Inc. (RAYT) is a public traded company incorporated in Nevada, USA since its inception in 2011. In 2018, the Company repositioned itself to focus on personalized natural healthcare industry.
Rayont uses scientific tools such as DNA, microbiome, iridology and other tests to personalize diagnoses, prescription and treatments of natural complementary and alternative medicine products, services and treatments to our patients in the markets we operate.
For further information, please visit
SAFE HARBOR
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, are subject to Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbors created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.
Company Contact:
Investor Relations
ir@rayont.com
Palo Alto, California, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Rayont Inc. ("Rayont" or the "Company") (OTC PINK: RAYT), an international personalized natural healthcare company, today reported financial results for the twelve-month ended June 30, 2022.
加利福尼亚州帕洛阿尔托，2022年12月29日(Global Newswire)--国际个性化自然保健公司Rayont Inc.(“Rayont”or“Company”)(场外交易代码：RAYT)今天公布了截至2022年6月30日的12个月的财务业绩。
Business Highlights Within the Twelve-Month ended June 30, 2022:
中的业务亮点十二-截至月底六月 30, 2022:
Ms. Marshini Moodley, CEO and CFO, said, "We recorded a decline in both the revenue and gross profit for the period ended 30 June 2022 compared to same period last year, mainly due to increase in cost of raw materials and lead time of supply chain in Prema Life operations. We also disposed Rayont Technologies operations in Australia and Malaysia resulting in drop of revenues and gross profit."
首席执行官兼首席财务官Marshini Moodley女士表示：“与去年同期相比，我们在截至2022年6月30日的期间的收入和毛利均有所下降，这主要是由于Prema Life业务的原材料成本和供应链提前期的增加。我们还出售了澳大利亚和马来西亚的Rayont Technologies业务，导致收入和毛利润下降。”
Twelve-month Ending June 30, 2022, Financial Results:
| |
|
Twelve Months Ended June 30, |
|
| |
|
2022 |
|
|
2021 |
|
| Revenues |
|
$ |
2,839,357 |
|
|
$ |
2,969,599 |
|
| Gross Profit |
|
$ |
1,382,624 |
|
|
$ |
1,748,573 |
|
| |
|
截至6月30日的12个月， |
|
| |
|
2022 |
|
|
2021 |
|
| 收入 |
|
$ |
2,839,357 |
|
|
$ |
2,969,599 |
|
| 毛利 |
|
$ |
1,382,624 |
|
|
$ |
1,748,573 |
|
Improved Balance Sheet Results
|
|
|
June 30,
2022
|
|
|
|
June 30,
2021
|
|
| Cash |
|
$ |
185,782 |
|
|
$ |
243,610 |
|
| Total Assets |
|
$ |
14,193,235 |
|
|
$ |
7,157,352 |
|
| Total Liabilities |
|
$ |
9,099,623 |
|
|
$ |
3,430,326 |
|
| Total Stockholders' Equity |
|
$ |
5,093,612 |
|
|
$ |
3,727,026 |
|
|
|
|
6月30日，
2022
|
|
|
|
6月30日，
2021
|
|
| 现金 |
|
$ |
185,782 |
|
|
$ |
243,610 |
|
| 总资产 |
|
$ |
14,193,235 |
|
|
$ |
7,157,352 |
|
| 总负债 |
|
$ |
9,099,623 |
|
|
$ |
3,430,326 |
|
| 股东权益总额 |
|
$ |
5,093,612 |
|
|
$ |
3,727,026 |
|
Marshini Moodley added, "Our yearly performance reflecting increased total asset portfolio and total stockholders' equity. The working capital deficit decreased from $1,456,964 that was on June 30, 2021, to $83,884 as of June 30, 2022. Our cash reserves have decreased due to capital investments and servicing loan interest received to cover different investments done from the Company during the year".
Marshini Moodley补充说：“我们的年度业绩反映了总资产组合和总股东权益的增加。营运资本赤字从$1,456,964那是在2021年6月30日，到$83,884截至2022年6月30日。我们的现金储备因资本投资及为支付本公司于年内作出的不同投资而收取的还本贷款利息而减少“。
During this financial year we continue to undertake several key activities aimed to improve the overall performance of Rayont Inc namely:
在本财政年度，我们继续开展旨在改善Rayont Inc.整体业绩的几项关键活动，即：
- Consolidate the operations of Prema Life with that of Tugun Compounding Pharmacy to drive cost reduction and efficiencies across both operations.
- Launch Health Script telehealth platform for naturopaths globally with key markets focus Australia and the USA.
- Continue with smaller acquisitions that can contribute to revenue growth and synergies across the group. We expect that the acquisitions made to date will contribute to significant revenue and profit growth this financial year.
- 将Prema Life的业务与Tugan复方药房的业务合并，以推动这两项业务的成本降低和效率提高。
- 为全球主要市场澳大利亚和美国推出面向自然疗法的Health脚本远程健康平台。
- 继续进行规模较小的收购，以促进整个集团的收入增长和协同效应。我们预计，到目前为止进行的收购将为本财年的收入和利润增长做出重大贡献。
These activities are being worked on and we will communicate their completions as we achieve them.
这些活动正在进行中，我们将在实现它们时通报它们的完成情况。
Rayont, Inc. (RAYT) is a public traded company incorporated in Nevada, USA since its inception in 2011. In 2018, the Company repositioned itself to focus on personalized natural healthcare industry.
Rayont，Inc.(RAYT)是一家上市公司，自2011年成立以来一直在美国内华达州成立。2018年，公司重新定位，专注于个性化的自然保健行业。
Rayont uses scientific tools such as DNA, microbiome, iridology and other tests to personalize diagnoses, prescription and treatments of natural complementary and alternative medicine products, services and treatments to our patients in the markets we operate.
Rayont使用DNA、微生物组、虹膜学和其他测试等科学工具，为我们运营的市场中的患者提供个性化的天然补充和替代医学产品、服务和治疗的诊断、处方和治疗。
For further information, please visit
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, are subject to Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbors created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.
本新闻稿中的某些陈述可能包含1933年《证券法》第175条规定的前瞻性信息，受1934年《证券交易法》第3b-6条的约束，并受这些规定所创造的安全港的约束。本新闻稿中包含的除事实陈述外的所有陈述，包括但不限于有关公司潜在的未来计划和目标的陈述，均为前瞻性陈述，涉及风险和不确定性。不能保证这样的陈述将被证明是准确的，其他结果和进一步的事件可能与这种陈述中预期的大不相同。未来的事件和实际结果可能与前瞻性陈述中陈述的、预期的或潜在的大不相同。
Company Contact:
Investor Relations
ir@rayont.com
公司联系人：
投资者关系
邮箱：ir@rayont.com
